おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified antibody
抗体製品タイプ
primary antibodies
クローン
1G3, monoclonal
交差性
human
テクニック
ELISA: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable
アイソタイプ
IgG1κ
NCBIアクセッション番号
UniProtアクセッション番号
輸送温度
wet ice
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... LGALS9(3965)
詳細
Galectin-9 (UniProt O00182; also known as Ecalectin, Gal-9, Tumor antigen HOM-HD-21, Urate transporter/channel protein) is encoded by the LGALS9 (also known as HUAT, LGALS9A) gene (Gene ID 3965) in human. The beta-galactoside-binding lectin, Galectin-9, possesses two distinct carbohydrate recognition domains (CRDs) linked together by a peptide domain of different length among the S, M, and L spliced isoforms. Galectin-9 plays a key role in a negative feed-back mechanism against Th1 immune response, where galectin-9 production from various cell types (e.g. fibroblasts and endothelial cells) is induced by interferon-gamma produced by CD4+ Th1 lymphocytes. The up-regulated galectin-9 in turn suppresses CD4+ Th1 lymphocytes, at least in part through stimulation of the Tim-3 receptor. The Tim-3 receptor on CD4+ Th1 cells from patients with multiple sclerosis (MS), rheumatoid arthritis, and auto-immune hepatitis is defective in its response to galectin-9. In addition, excessive galectin-9 production is reported in two human diseases associated with oncogenic viruses, nasopharyngeal carcinomas (NPC) associated with the Epstein-Barr virus (EBV) and chronic infection by the hepatitis C virus (HCV).
特異性
Clone 1G3 reacts with all three (L, M, and S) galectin-9 isoforms, but not galectin 1, 2, 3, 4, 7, 8, or 10.
免疫原
GST-tagged recombinant protein corresponding to human Galectin-9.
アプリケーション
Immunohistochemistry Analysis: A representative lot detected galectin-9 immunoreactivity in hepatocytes as well as inflammatory leucocytes and Kupffer cells in paraffin-embedded liver sections from patients with hepatitis C or B infection, but not in non-infected liver specimens (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
Immunohistochemistry Analysis: A representative lot detected galectin-9 immunoreactivity in malignant cells using various paraffin-embedded nasopharangeal carcinoma (NPC) tissue sections (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
Western Blotting Analysis: A representative lot detected endogenous galectin-9 isoforms in HeLa, lymphoblastoid cell line (LCL) REMB1, and nasopharyngeal carcinoma (NPC) cell lines C15 & C666-1, as well as exogenously expressed galectin-9 isoforms in transfected HeLa cells, but not in Burkitt’s lymphoma (BL) BL2 cells (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
ELISA Analysis: A representative lot selectively captured human & murine galectin-9 (mGal-9 M, hGAL-9 S & M isoforms), but not human galectin 1, 2, 3, 4, 7, 8, or 10 (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
Immunocytochemistry Analysis: A representative lot detected galectin-9 immunoreactivity in formalin-fixed and paraffin-embedded lymphoblastoid cell line (LCL) REMB1, but not in Burkitt’s lymphoma (BL) BL2 cells (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
Immunohistochemistry Analysis: A representative lot detected galectin-9 immunoreactivity in malignant cells using various paraffin-embedded nasopharangeal carcinoma (NPC) tissue sections (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
Western Blotting Analysis: A representative lot detected endogenous galectin-9 isoforms in HeLa, lymphoblastoid cell line (LCL) REMB1, and nasopharyngeal carcinoma (NPC) cell lines C15 & C666-1, as well as exogenously expressed galectin-9 isoforms in transfected HeLa cells, but not in Burkitt’s lymphoma (BL) BL2 cells (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
ELISA Analysis: A representative lot selectively captured human & murine galectin-9 (mGal-9 M, hGAL-9 S & M isoforms), but not human galectin 1, 2, 3, 4, 7, 8, or 10 (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
Immunocytochemistry Analysis: A representative lot detected galectin-9 immunoreactivity in formalin-fixed and paraffin-embedded lymphoblastoid cell line (LCL) REMB1, but not in Burkitt’s lymphoma (BL) BL2 cells (Barjon, C., et al. (2012). Infect Agent Cancer. 7(1):16-26).
This Anti-Galectin-9 Antibody, clone 1G3 is validated for use in Western Blotting, Immunohistochemistry (Paraffin), ELISA and Immunocytochemistry for the detection of Galectin-9.
品質
Evaluated by Western Blotting in HeLa nuclear extract.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected Galectin-9 in 10 µg of HeLa nuclear extract.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected Galectin-9 in 10 µg of HeLa nuclear extract.
ターゲットの説明
~38 kDa observed
物理的形状
Format: Purified
その他情報
Concentration: Please refer to lot specific datasheet.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
MABT833:
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses.
Barjon, C; Niki, T; Verillaud, B; Opolon, P; Bedossa, P; Hirashima, M; Blanchin et al.
Infectious Agents and Cancer null
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)